Drugs firm Aspen is to pay the NHS £8 million following an investigation into the supply of a life-saving drug to thousands of patients across the country.
It is the first time the Competition and Markets Authority (CMA) will secure such a payment to the NHS in one of its pharmaceutical investigations. It follows an investigation conducted by the CMA into suspected anti-competitive arrangements regarding the supply of fludrocortisone acetate 0.1 mg tablets.
Thousands of NHS patients depend on fludrocortisone, which is only available on prescription, usually to treat primary or secondary adrenal insufficiency, more commonly known as Addison’s Disease. The drug is paid for by the NHS and, ultimately, the UK taxpayers.